Pivotal Hearing on Opioid Crisis and Healthcare Affordability
The House Energy and Commerce Committee will hold a pivotal hearing on June 25 to address two major public health issues: the synthetic opioid crisis and healthcare affordability. Lawmakers plan to review 15 legislative proposals, focusing on priorities outlined in the 2026 National Drug Control Strategy, alongside challenges faced by seniors due to insurance-related care access issues.
The 2026 National Drug Control Strategy identifies synthetic opioids like nitazenes and cutting agents such as xylazine as significant threats, as they are trafficked directly to U.S. drug dealers. The strategy warns that seemingly legitimate businesses may exacerbate the drug crisis. Meanwhile, the Centers for Medicare & Medicaid Services (CMS) introduced revised hospital price transparency regulations on April 1, 2026, prompting congressional review to ensure regulatory compliance.
A key bill under consideration is the STOP Nitazenes Act, aiming to classify certain nitazene compounds, such as etonitazene and metonitazene, as Schedule I controlled substances. This legislation would include chemically similar compounds affecting opioid receptors under the same classification.
The Combating Illicit Xylazine Act seeks to categorize xylazine as a Schedule III substance while protecting its veterinary use. It allows veterinarians to prescribe and pharmacies to dispense xylazine for animals. The bill outlines a 60-day compliance period for practitioner registration and a year to meet labeling standards. It also requires DEA and FDA reports to Congress on illicit xylazine risks within set timelines.
The Improving Seniors' Timely Access to Care Act of 2025 focuses on Medicare prior authorization reforms. It mandates Medicare Advantage plans to disclose services requiring prior authorization and report approval rates by 2027. By 2028, these plans must adopt a standardized electronic prior authorization system. Additionally, CMS is tasked with identifying services eligible for expedited prior authorization. The bill enjoys bipartisan support with 290 cosponsors.
The markup hearing on June 25, 2026, will spotlight these legislative efforts to combat illegal drugs and enhance healthcare price transparency. The outcomes could significantly influence regulatory measures and healthcare access for seniors.